Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Avience Biomedicals Ltd IPO
Avience Biomedicals Ltd
₹2,35,200 /1200 sharesMinimum investment
IPO details
Minimum investment
₹2,35,200
Price range
₹196 - ₹208
Lot size
600
Issue size
30.24 Cr
Face value
10
IPO document
Subscription rate
Data will be available soon
Schedule
18 Jun 2026
IPO open date
22 Jun 2026
IPO close date
23 Jun 2026
Allotment date
23 Jun 2026
Funds unblock or debit
25 Jun 2026
Tentative listing date
About
Founded in
2019
MD/CEO
Mr Dharam Deo Choudhary
Parent organisation
Avience Biomedicals Ltd
Avience Biomedicals Financials
Revenue
Total Assets
Profit
All values are in ₹ Cr
Strengths & Risks
Strengths
Risks
The company claims to have a diversified portfolio of in-vitro diagnostic (IVD) products and medical devices. Its offerings include rapid diagnostic test kits for infectious diseases, serology products, biochemistry reagents, culture media, biochemistry analysers, and haematology equipment, catering to a broad range of healthcare and diagnostic requirements.
The company is ISO:13485 certified for medical device quality management systems and ISO:9001 certified for quality management systems. It also claims that its products comply with CE standards and Good Manufacturing Practices (GMP), which are commonly used quality and manufacturing benchmarks in the medical device industry.
The company operates both as a manufacturer of diagnostic products and a distributor and trader of medical equipment. In addition, it is a channel partner for Mindray, allowing it to offer biochemistry analysers and haematology equipment alongside its own product portfolio.
The company claims to have an in-house team of service engineers that provides installation, training, and maintenance support for medical equipment. This allows it to offer post-sales technical support to laboratories, hospitals, and healthcare facilities using its products and equipment.
The company has established a manufacturing facility in Noida, Uttar Pradesh, and has also been allotted industrial land in the Medical Device Park at YEIDA. The proposed facility within the medical device park can provide access to an ecosystem of healthcare, research, and medical device companies.
The company has developed a presence across multiple customer segments, including distributors, traders, hospitals, diagnostic laboratories, research centres, and government organisations. It generates revenue through B2B, B2C, B2G, and export channels, providing diversification in its customer base.
The company claims to have an international marketing team focused on exploring overseas opportunities and participating in international exhibitions. The company also derives a portion of its revenue from exports, indicating exposure to markets outside India.
The company’s top 10 customers contributed Rs 13.35 crore (46.44%), Rs 16.35 crore (56.82%), Rs 11.23 crore (69.12%), and Rs 8.17 crore (74.79%) of revenue from operations during the period ended January 31, 2026, FY25, FY24, and FY23, respectively. Any loss of these key customers, a reduction in orders, or failure to maintain relationships with them could adversely affect the company’s business, cash flows, and financial performance.
The company depends on third-party suppliers for traded medical devices, diagnostic equipment, laboratory reagents, consumables, surgical instruments, and raw materials used in its manufacturing operations. Since orders are generally placed on a requirement basis and the company does not typically have long-term or exclusive supply agreements with its suppliers, any disruption in the supply chain could adversely affect its business operations and financial condition. Any delays or failures by suppliers due to regulatory issues, financial difficulties, facility disruptions, labour unrest, power outages, or geopolitical events could result in higher procurement costs, production delays, and operational disruptions. If the company is required to source materials from alternative suppliers, it may face additional costs and delays, which could negatively impact its profitability and cash flows.
The company derives a significant portion of its revenue from trading activities, which contributed Rs 19.67 crore (68.44%), Rs 20.89 crore (72.31%), Rs 12.94 crore (79.60%), and Rs 9.15 crore (83.81%) of revenue from operations during the period ended January 31, 2026, FY25, FY24, and FY23, respectively. This indicates a substantial dependence on the trading segment despite the company’s efforts to expand its manufacturing operations. Any slowdown in demand for traded products, disruption in the procurement of traded goods, pricing pressure, or loss of key trading relationships could adversely affect the company’s revenue and profitability.
The company requires significant working capital to support its trading and manufacturing operations. Its working capital requirement stood at Rs 11.69 crore as of January 31, 2026, and is estimated to increase to Rs 20.49 crore in FY27 and Rs 29.01 crore in FY28. The company needs to maintain inventory levels and fund customer orders, which could increase its dependence on external financing and internal accruals. If it is unable to secure additional funding on favourable terms, manage working capital efficiently, or collect receivables on time, that could adversely affect its expansion plans, cash flows, financial condition, and business operations.
The company is highly dependent on a limited number of suppliers for the procurement of raw materials, medical devices, and other products. Its top 10 suppliers accounted for Rs 15.67 crore (82.69%), Rs 15.27 crore (87.47%), Rs 13.78 crore (91.28%), and Rs 9.24 crore (93.79%) of total purchases during the period ended January 31, 2026, FY25, FY24, and FY23, respectively. Any disruption in relationships with these suppliers, delays in supply, or inability to source materials from alternative vendors on similar commercial terms could adversely affect the company’s production, operations, cash flows, and financial condition.
The company has reported negative cash flows from investing activities in recent years due to significant capital expenditure on land, plant, and equipment. It recorded negative cash flows from investing activities of Rs 8.34 crore, Rs 8.16 crore, Rs 4.12 crore, and Rs 1.94 crore during the period ended January 31, 2026, FY25, FY24, and FY23, respectively. As a result, the company reported a net decrease in cash and cash equivalents of Rs 3.24 crore during the period ended January 31, 2026, and Rs 0.09 crore in FY24. If the company’s capital expenditure and investment requirements continue to exceed cash generation from operations, it may require additional funding, which could adversely affect its liquidity, cash flows, and financial condition.
The company’s revenue is heavily concentrated in a few states, with its top five states contributing approximately 90.51% of domestic sales as of January 31, 2026. Delhi contributed Rs 12.12 crore (42.15%) of revenue, followed by Uttar Pradesh at Rs 9.78 crore (34.03%), Haryana at Rs 2.57 crore (8.94%), Manipur at Rs 0.80 crore (2.80%), and Odisha at Rs 0.74 crore (2.58%). Any adverse economic, regulatory, political, or operational developments in these regions, including policy changes, disruptions in healthcare spending, natural disasters, or local economic slowdowns, could materially affect the company’s revenue generation and financial performance. The high dependence on a limited number of states increases the company’s exposure to regional concentration risks.
The company, its promoters, and directors are involved in certain ongoing legal proceedings. Any adverse outcome in these matters could result in financial liabilities, regulatory actions, or reputational damage, which may adversely affect the company’s business operations and financial condition. Any unfavourable judgment, settlement, or penalty arising from these cases could hurt the company’s reputation, cash flows, and future business prospects.
As of January 31, 2026, the company had total outstanding borrowings of Rs 26.73 crore from banks, financial institutions, and other lenders. These borrowings include working capital facilities, term loans, vehicle loans, and unsecured loans, secured against the company’s assets, land, machinery, inventories, receivables, and properties of promoters and directors. Any inability to service or repay these borrowings, comply with loan covenants, or renew existing credit facilities could adversely affect the company’s operations and financial condition.
Application details
For Avience Biomedicals IPO, eligible investors can apply as Individual investor.
| Apply as | Price band | Apply range | Lot size |
|---|---|---|---|
| Individual investor | ₹196 - ₹208 | ₹2 - ₹5 Lakhs | 600 |